[Rich66]

HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of Evil

Hasan Korkaya and Max S. Wicha Authors' Affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Requests for reprints: Max S. Wicha, Department of Internal Medicine/Oncology, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0015. Phone: 734-647-9923; Fax: 734-647-9480; E-mail: mwicha@med.umich.edu.
Abstract
Increasing evidence indicates that tumor-initiating (cancer stem) cells may contribute to treatment resistance and relapse, suggesting that improved clinical outcome will require effective targeting of this cell population. Recent studies suggest that the remarkable clinical efficacy of trastuzumab may relate to its ability to target cancer stem cell populations.

1. » Abstract
2. Full Text
3. Full Text (PDF)
4. Related Article